Genelux (GNLX) Operating Income (2022 - 2026)

Genelux's (GNLX) quarterly Operating Income came in at -$9.2 million in Q1 2026, down 17.34% year-on-year from -$11.1 million in Q1 2025, and up 2.56% quarter-over-quarter from -$9.4 million in Q4 2025.

Genelux (GNLX) Operating Income (2022 - 2026) Analysis & Trends

Genelux's Operating Income history runs 5 years deep, the most recent figure standing at -$9.2 million for Q1 2026.

  • On a quarterly basis, Operating Income fell 17.34% year-over-year to -$9.2 million in Q1 2026; TTM through Mar 2026 was -$34.6 million, a 10.1% decrease from a year earlier, with the FY2025 full-year figure at -$33.2 million, down 4.79% from the prior year.
  • Operating Income rose to -$9.2 million in Q1 2026 per GNLX's latest filing, from -$9.4 million in the prior quarter.
  • Across five years, Operating Income topped out at $6.3 million in Q3 2022 and bottomed at -$9.7 million in Q4 2024.
  • The 5-year median for Operating Income is -$7.0 million (2023), against an average of -$6.3 million.
  • Across the five-year window, Operating Income slumped 183.65% in 2023 and grew 3.68% in 2025, its largest moves.
  • Year by year, Operating Income stood at -$3.1 million in 2022, then slumped by 126.28% to -$7.0 million in 2023, then tumbled by 39.24% to -$9.7 million in 2024, then grew by 3.45% to -$9.4 million in 2025, then climbed by 2.56% to -$9.2 million in 2026.
  • Per Business Quant, the three latest GNLX Operating Income figures stand at -$9.2 million (Q1 2026), -$9.4 million (Q4 2025), and -$8.2 million (Q3 2025).

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc (Qtr)
1 Oculis Holding AG 65,899.61 Bn 65,899.33 Bn - -27.75 Mn
2 Nanobiotix 1,933.82 Bn 1,933.76 Bn - -
3 Akari Therapeutics 1,022.34 Bn 1,022.34 Bn - -15.76 Mn
4 BeOne Medicines 472.68 Bn 467.89 Bn 1.35 Bn 249.90 Mn
5 Vertex Pharmaceuticals 122.24 Bn 114.99 Bn 2.59 Bn 1.14 Bn
6 Regeneron Pharmaceuticals 70.08 Bn 61.33 Bn 3.31 Bn 642.90 Mn
7 Belite Bio 62.46 Bn 62.46 Bn - -32.68 Mn
8 Argenx Se 55.93 Bn 50.75 Bn 1.41 Bn 493.00 Mn
9 Alnylam Pharmaceuticals 37.59 Bn 34.58 Bn 959.66 Mn 268.64 Mn
10 Genelux 129.36 Mn 129.36 Mn - -9.17 Mn

Historic Data

Download Data
DateValue
Mar 31, 2026 -9.17 Mn
Dec 31, 2025 -9.41 Mn
Sep 30, 2025 -8.19 Mn
Jun 30, 2025 -7.79 Mn
Mar 31, 2025 -7.82 Mn
Dec 31, 2024 -9.75 Mn
Sep 30, 2024 -6.94 Mn
Jun 30, 2024 -6.89 Mn
Mar 31, 2024 -8.12 Mn
Dec 31, 2023 -7.00 Mn
Sep 30, 2023 -5.31 Mn
Jun 30, 2023 -5.40 Mn
Mar 31, 2023 -6.46 Mn
Dec 31, 2022 -3.09 Mn
Sep 30, 2022 6.34 Mn